Navigation Links
Labopharm settles $1 million draw down under standby equity distribution agreement
Date:1/8/2010

LAVAL, QC, Jan. 8 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced it has settled the previously announced draw down of $1 million under its standby equity distribution (SEDA) with YA Global Master SPV Ltd. (YA). Under the draw down, Labopharm issued 482,165 of its common shares to YA at a price of $2.07 per common share, net of the applicable discount. (All currency figures are in Canadian dollars.)

In accordance with the terms of the SEDA, the common shares were issued at a discount of 5% to the volume weighted average price (VWAP) on the Toronto Stock Exchange over the ten consecutive trading days following Labopharm's notice of its intention to draw down on the SEDA on December 20, 2009.

Following the completion of the issuance of shares to YA, Labopharm has 57,938,529 shares outstanding.

In connection with the draw down, Labopharm has filed a prospectus supplement to its short-form base shelf prospectus and registration statement to qualify the shares issued to YA. Copies of the final short-form base shelf prospectus, registration statement and prospectus supplement have been filed with SEDAR (www.sedar.com) and EDGAR (www.sec.gov) or may be obtained upon request to the Labopharm contact information below.

Securities Laws Matters

Securities legislation in certain of the provinces of Canada provides purchasers with the right to withdraw f
'/>"/>

SOURCE Labopharm Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe
2. Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement
3. Labopharm Reports Results for Third Quarter Fiscal 2009
4. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
5. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
6. Labopharm submits response to FDA for novel antidepressant
7. Labopharm Reports Results for Second Quarter Fiscal 2009
8. Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
9. Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
10. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
11. Labopharm amends debt facility agreement with Hercules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Recently, iFitDress.com, one of the most famous ... of top bridesmaid dresses online. At the moment, ... up to 52% off. According to the company’s senior spokesman, ... , The company’s stock is limited. Those who are ... store as soon as possible. All its products are delicately ...
(Date:8/1/2014)... 2014 Cannabis use among young people has ... to 17 having used marijuana at least once and 17 ... “Say ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers from ... youth this summer with factual information about drugs, to help ... Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” volunteers ...
(Date:8/1/2014)... 2014 The Judicial Panel on Multidistrict ... replacement therapy caused strokes, heart attacks, and other injuries ... Matthew F. Kennelly as the transferee judge and ordered ... Chicago-based federal court. , As one of his first ... committees of attorneys who will move the litigation forward ...
(Date:8/1/2014)... San Diego School of Medicine report that dietary capsaicin ... chronic activation of a receptor on cells lining the ... the risk of colorectal tumors. , The findings are ... The Journal of Clinical Investigation . , The receptor ... sensory neurons, where it acts as a sentinel for ...
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Study reveals one reason brain tumors are more common in men 2
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... www.stressballsuk.com ... points to an economic upturn and possibly the beginning of the end of the credit ... (PRWEB) March 2, ... to an economic upturn and possibly the beginning of the end of the credit crunch., ...
... ... event focusing on insights into the exploding field of neuroscience, what this means for ... the most effective ways to motivate and generate transformation in organisations – all leading ... ...
... ... to fill the gap in poor physician adherence to low back pain management guidelines with the ... ... for the iPhone platform this week to help bridge an expensive health care gap. The ...
Cached Medicine News:Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 2Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 3Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 4Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 5Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 6Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 7Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 8Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 9Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 10Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 11Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 12Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 13Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 14Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 2Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 3Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 2Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 3Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 5Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 6Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 7Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 8Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 9Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 10Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 11Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 12Health News:Promotional Stress Ball Supplier -- StressBallsUK.com Starts 2010 Strongest Ever 2Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines 2
(Date:8/1/2014)... PLAINFIELD, N.J. , Aug. 1, 2014  PTC ... that on July 31, 2014 it approved non-statutory stock ... its common stock to seven new employees. The awards ... as a component of our new hires, employment compensation. ... Compensation Committee on July 31, 2014 and are being ...
(Date:8/1/2014)... , Aug. 1, 2014  With monumental health ... to speak a second language. Clinical efficacy is no ... established under the ACA like PCORI are directing roughly ... variety of new entities and environments, the federal healthcare ... the new language of outcomes and managed markets to ...
(Date:8/1/2014)... and NEW YORK , ... VRX) and Pershing Square Capital Management, L.P. today responded ... Inc. (NYSE: AGN ) in California.  The ... regarding the tender offer rules.  Allergan,s ... to interfere with shareholders, efforts to call a special ...
Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
... Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) ... ) and Cephalon, Inc. (NASADQ: CEPH) on their announcement that ... to the news, Valeant has withdrawn its consent solicitation. ... for Cephalon stockholders and we are pleased that Teva has ...
... Solutions, Inc. (OTCQB: VHSLD) announced that it will begin ... Financial Industry Regulatory Authority has approved a change in ... ticker change has gone into effect for the trading ... the "D" will be removed from the ticker symbol ...
Cached Medicine Technology:Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction 2Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change 2
Designed for use during surgical procedures under fluoroscopy. A very practical unit, the frames superior design eliminates problems associated with imaging....
Low temp, micro fine tip, patented Aaron RAM cauteries....
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: